UPDATE: Oppenheimer Maintains Outperform Rating, Raises PT for Thoratec

Loading...
Loading...
In a quarterly update released earlier today, Oppenheimer & Co. Inc. maintained its Outperform rating for Thoratec Corporation
THOR
and raised its price target from $40.00 to $42.00. Oppenheimer said its decision “is predicated on our belief that the Left Ventricular Assist Device (LVAD) market is one of the big growth opportunities in medtech. THOR will be the only company with an indication for the larger destination therapy segment of the US market for the next three years. We estimate the market will grow at a high-teens five-year CAGR from sub $400M in 2010 to $1B by 2015.” Thoratec Corporation closed yesterday at $34.50.
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsOppenheimer & Co. Inc.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...